Drug licensing deal brings millions in Israeli capital to Burnaby

Israel’s Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has announced that it will pay Burnaby-based Xenon Pharmaceuticals Inc. up to $376 million for a worldwide license to ...

Israel’s Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has announced that it will pay Burnaby-based Xenon Pharmaceuticals Inc. up to $376 million for a worldwide license to a pain drug that Xenon is developing.

The deal will see Teva pay Xenon $41 million up front, and then fund up to $335 million in “development, regulatory and sales-based milestones” for Xenon’s drug, XEN402. For its investment, Teva will obtain an exclusive worldwide license for the drug. Xenon will be entitled to royalties payable on sales and an option to participate in commercialization in the U.S.

Jeremy Levin, president and CEO of Teva, welcomed the deal.

“[This drug] holds the potential to address the significant unmet medical need for the many patients who suffer from chronic pain,” he said. “In addition, XEN402 has the potential for broader therapeutic use across other pain conditions.”

Simon Pimstone, president and CEO of Xenon, also expressed satisfaction with the deal.

“This partnership with Teva,” he said, “is Xenon’s seventh major pharmaceutical alliance, once again highlighting the value of Xenon’s unique genetics approach and translational R&D capabilities.”

The drug is currently in clinical development.

jwagler@biv.com

@JennyWagler_BIV

comments powered by Disqus

More from Technology

PayPal acquires Vancouver-based TIO Networks in $304m deal

Read Article

B.C. fintech to get better road map from regulators

B.C. Securities Commission follows Ontario’s lead with launch of team to help financial technology firms

Read Article

BIV on Global BC February 6, 2017: CRTC to review wireless code

Tyler Orton discusses the CRTC's review of the code of conduct for wireless companies.

Read Article

BIV on Global BC February 3, 2017: Snap Inc. going public, Amazon ...

Read Article

Subscribe to our mailing lists

* indicates required

Newsletters

* You can modify your newsletter subscriptions at the bottom of any newsletter you receive.
×